Biologics are the most expensive drug category in the United States. A recent study, published in the Journal of Managed Care and Specialty Pharmacy, investigated how American health systems are reacting to the introduction of biosimilars into the marketplace, and described real-world implementation strategies.
Biologics are the most expensive drug category in the United States. A recent study, published in the Journal of Managed Care and Specialty Pharmacy, investigated how American health systems are reacting to the introduction of biosimilars into the marketplace, and described real-world implementation strategies.
To maximize the potential impact of biosimilars, health care providers, payers, and biosimilar manufacturers must understand where and how biosimilars bring the most value to patients. In order to gain insight from health system experiences with the first infliximab biosimilar (Inflectra) approved in the US, a questionnaire was distributed to pharmacy representatives from health systems during March and April 2017. Responses were collected from 57 health systems across the country, and revealed that the key barriers and challenges faced with biosimilar uptake include payers and reimbursement, interchangeability, provider preference, and cost.
Financial Concerns
All health systems that responded to the questionnaire had used the reference infliximab product within their respective organizations. When asked about potential cost savings with the infliximab biosimilar:
Clinical concerns
After financial barriers for payers and reimbursement, interchangeability and switching patient therapy were identified by 20% of respondents as the next greatest barrier to infliximab biosimilar uptake. Provider and patient preferences were identified by the study as the third greatest barrier (14%), with immunogenicity and clinical safety highlighted as well (6%).
Operational concerns
The study explained that health systems work to streamline and standardize inventory, so if a decision is made to keep a biosimilar and reference product on hand, additional steps may be required to ensure appropriate management of the products. In fact, a small percentage (2%) of questionnaire respondents mentioned stocking multiple products as another barrier for infliximab biosimilar use.
The potential cost-savings from biosimilars has been estimated to be $44.2 billion over a 10-year timeframe, according to the study. Yet concerns must be overcome to truly realize the benefits. With increasing pressure to reduce the overall cost of health care, biosimilars have the potential to intensify competition in the biologics space. According to the study, ideally the biosimilar movement will affect healthcare much like the introduction of generic drugs did years ago: by increasing competition, driving down costs, and maintaining optimal patient outcomes.
Samsung Bioepis Report Signals Turning Point for US Biosimilars
May 1st 2025A wave of biosimilar approvals, aggressive pricing strategies, and a regulatory sea change are setting the stage for unprecedented momentum in the US biologics market, with 2025 already proving to be a landmark year in reshaping cost, access, and innovation across therapeutic areas.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Eye on Pharma: Sandoz Files Antitrust Suit; Yuflyma Interchangeability; Costco’s Ustekinumab Pick
April 22nd 2025Sandoz's antitrust suit against Amgen, the FDA’s interchangeability designation for Celltrion’s adalimumab biosimilar, and the inclusion of an ustekinumab biosimilar in Costco’s prescription program highlight growing momentum to expand biosimilar access and affordability for patients with chronic inflammatory diseases.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
How State Substitution Laws Shape Insulin Biosimilar Adoption
April 15th 2025States with fewer restrictions on biosimilar substitution tend to see higher uptake of interchangeable insulin glargine, showing how even small policy details can significantly influence biosimilar adoption and expand access to more affordable insulin.
Latest Biosimilar Deals Signal Growth Across Immunology, Oncology Markets
April 14th 2025During Q1 2025, pharmaceutical companies accelerated biosimilar expansion through strategic acquisitions and partnerships in hopes of boosting patient access to lower-cost treatments in immunology and oncology.